Pyroptosis In Alopecia Areata: Synthesizing Emerging Hypotheses And Charting A Path To New Therapies

November 2025 in “ Biomedicines ”

Mateusz Łysek, Justyna Putek, Beata Jastrząb-Miśkiewicz, Jacek C. Szepietowski, Piotr K. Krajewski

pyroptosis alopecia areata autoimmune hair loss inflammasomes outer root sheath keratinocytes cytokine release JAK inhibitors PDE4 inhibitors inflammasome inhibitors

Studysummary In this review, researchers reported that pyroptosis, a type of inflammatory cell death linked to inflammasome activity, is a key factor in the pathogenesis of alopecia areata and may present new therapeutic opportunities, though most treatments are still in early research stages.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The review examines the role of pyroptosis, an inflammatory form of programmed cell death, in the development of alopecia areata (AA), an autoimmune hair loss disorder. It highlights the involvement of inflammasomes, particularly in outer root sheath keratinocytes, which contribute to cytokine release and inflammation, exacerbating hair follicle damage. The study suggests that targeting pyroptosis through various therapeutic strategies, such as JAK inhibitors, PDE4 inhibitors, and inflammasome inhibitors, could be promising for new AA treatments. However, these approaches are mostly in early stages, and further research is needed to validate their efficacy in reducing disease relapse and supporting hair regrowth in AA patients.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

45 / 45 results

research Immune-Mediated Disorders in Patients With Alopecia Areata: Systematic Review and Meta-Analysis

7 citations , July 2025 in “International Journal of Dermatology”

This meta-analysis found that patients with alopecia areata have significantly higher odds of also having immune-mediated diseases such as atopic dermatitis, autoimmune thyroiditis, inflammatory bowel disease, systemic lupus erythematosus, and vitiligo, suggesting a need for comprehensive screening and interdisciplinary management.

research Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study

15 citations , January 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

research Comparing the Efficacy of Oral Apremilast, Intralesional Corticosteroids, and Their Combination in Patients With Patchy Alopecia Areata: A Randomized Clinical Controlled Trial

4 citations , December 2024 in “Archives of Dermatological Research”

research Total Glucosides of Paeony Inhibit NLRP3/Caspase-1/GSDMD-Mediated Inflammation and Pyroptosis in C3H/HeJ Mice With Alopecia Areata

5 citations , September 2024 in “Biomolecules and Biomedicine”

This study found that total glucosides of paeony (TGP) reduced hair loss and inflammation in alopecia areata mice by inhibiting cellular pyroptosis.

research Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model

August 2024 in “International Journal of Molecular Sciences”

In this animal study, researchers found that local administration of mesenchymal stem cell therapy improved hair regrowth and reduced local inflammatory cytokines in mice with Alopecia Areata, although systemic cytokine levels were unchanged.

research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

research Interleukin-15 Is a Hair Follicle Immune Privilege Guardian

1 citations , April 2024 in “Journal of Autoimmunity”

This study found that rhIL-15 promotes human hair follicle growth and regrowth in experimental settings and may have therapeutic potential for alopecia areata by restoring immune privilege guardianship.

research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2

February 2024 in “Journal of the European Academy of Dermatology and Venereology”

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

research Advances In The Mechanism And New Therapies Of Alopecia Areata

October 2023 in “International journal of rheumatic diseases”

This study found that the JAK3/TEC kinase inhibitor ritlecitinib was effective and well tolerated in patients aged 12 and older with alopecia areata, providing a potential systemic treatment option for this condition, especially in cases of significant psychosocial impact.

research The Crosstalk Between PTEN-Induced Kinase 1-Mediated Mitophagy and the Inflammasome in the Pathogenesis of Alopecia Areata

6 citations , June 2023 in “Experimental Dermatology”

In this study, researchers found that inducing mitophagy can alleviate NLRP3 inflammasome activation in outer root sheath cells under conditions of mitochondrial stress, suggesting that targeting mitophagy and inflammasome interactions may offer new therapeutic approaches for alopecia areata.

research Aberrant Inflammasome Activation as a Driving Force of Human Autoimmune Skin Disease

3 citations , May 2023 in “Frontiers in immunology”

This study reviewed the role of inflammasomes in autoimmune skin diseases, highlighting their contribution to the pathogenesis of conditions such as vitiligo, alopecia areata, and psoriasis, and suggesting that targeting inflammasome dysregulation may offer new therapeutic options.

research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata

2 citations , December 2022 in “PNAS nexus”

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

research Alopecia Areata and Risk of Atopic and Autoimmune Conditions: Population-Based Cohort Study

34 citations , November 2022 in “Clinical and Experimental Dermatology”

This study found that individuals with AA have a higher incidence of atopic and autoimmune conditions, suggesting both Th1 and Th2 immune responses may play a role in its development.

Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata

research Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata

1 citations , October 2022 in “International Journal of Molecular Sciences”

This study suggests that allogenic human mesenchymal stem cell treatments have potential therapeutic effects by inducing immune tolerance and anti-inflammatory effects in severe alopecia areata patients.

research Two Phase III Trials of Baricitinib for Alopecia Areata: A Critically Appraised Research Paper

5 citations , October 2022 in “British Journal of Dermatology”

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

research Dupilumab for Alopecia Areata Treatment: A Double-Edged Sword?

2 citations , June 2022 in “Journal of cosmetic dermatology”

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

research Lifestyle Factors Involved in the Pathogenesis of Alopecia Areata

16 citations , January 2022 in “International journal of molecular sciences”

This review summarizes the influences of lifestyle factors such as smoking, alcohol, and diet on the pathogenesis of alopecia areata but reports no new clinical results.

research The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications

37 citations , December 2021 in “Cells”

This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.

research Hair-Growth Promoting Effect and Anti-Inflammatory Mechanism of Ginkgo Biloba Polysaccharides

11 citations , October 2021 in “Carbohydrate Polymers”

In this study, WGBP-A2 polysaccharides from Ginkgo biloba leaves promoted hair growth and altered inflammation markers in alopecia areata mice, suggesting potential therapeutic effects through modulation of inflammation pathways.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles

14 citations , April 2021 in “International journal of molecular sciences”

This study found that human hematopoietic mesenchymal stem cells increased the viability and migration of human outer root sheath cells in an in vitro alopecia areata model, involving Wnt/β-catenin and JAK/STAT pathways.

research The Antiinflammatory Effects of Xuefu Zhuyu Decoction on C3H/HeJ Mice With Alopecia Areata

18 citations , November 2020 in “Phytomedicine”

research Platelet-Rich Plasma in the Treatment of Alopecia Areata: A Review

15 citations , October 2020 in “Journal of Investigative Dermatology Symposium Proceedings”

This review discusses the potential use of platelet-rich plasma for treating alopecia areata but reports no new experimental findings, noting the need for standardized protocols and larger studies to evaluate its efficacy.

research The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells

16 citations , July 2020 in “International Journal of Molecular Sciences”

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

research Serum Level of Interleukin-15 in Active Alopecia Areata Patients and Its Relation to Age, Sex, and Disease Severity

14 citations , January 2020 in “Advances in Dermatology and Allergology”

This study found that elevated serum levels of IL-15 in active alopecia areata patients are correlated with disease severity, suggesting it plays a role in disease pathogenesis.

research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?

29 citations , December 2019 in “Expert review of clinical pharmacology”

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations , October 2019 in “Frontiers in Immunology”

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

research Efficacy of the Phosphodiesterase-4 Inhibitor, Apremilast, in a Patient with Severe Alopecia Areata

10 citations , August 2019 in “European Journal of Dermatology”

This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.

$Apremilast Is Efficacious in Refractory Alopecia Areata$

research Apremilast Is Efficacious in Refractory Alopecia Areata

9 citations , May 2019 in “Journal of dermatological treatment”

This article reviews characteristics and mental health impacts of alopecia areata but provides no new clinical findings; future research is encouraged.

research Pathomechanisms of Immune-Mediated Alopecia

45 citations , April 2019 in “International Immunology”

This review discusses the mechanisms behind alopecia areata and primary cicatricial alopecia and reports no new clinical results, aiming to guide the development of targeted treatments.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , December 2018 in “Journal of autoimmunity”

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

42 citations , November 2018 in “Archives of dermatological research”

Apremilast was not effective in treating moderate-to-severe alopecia areata.

research Response to Ustekinumab in Three Pediatric Patients with Alopecia Areata

25 citations , October 2018 in “Pediatric dermatology”

In this study, three pediatric patients with alopecia areata demonstrated hair regrowth after being treated with ustekinumab.

research Alopecia Areata: A Review of Disease Pathogenesis

191 citations , May 2018 in “British journal of dermatology/British journal of dermatology, Supplement”

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

research Alopecia Areata: Overview and Insights from January 2018

290 citations , December 2017 in “Journal of The American Academy of Dermatology”

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

Double-Stranded RNA Induces Inflammation via the NF-κB Pathway and Inflammasome Activation in the Outer Root Sheath Cells of Hair Follicles

research Double-Stranded RNA Induces Inflammation via the NF-κB Pathway and Inflammasome Activation in the Outer Root Sheath Cells of Hair Follicles

22 citations , March 2017 in “Scientific reports”

This study investigated the role of NLRP3 inflammasomes in alopecia areata and found that outer root sheath cells may contribute to inflammation by increasing IL-1β and HMGB1 secretion when stimulated with double-stranded RNA.

research Simvastatin/Ezetimibe Therapy for Recalcitrant Alopecia Areata: An Open Prospective Study of 14 Patients

13 citations , January 2017 in “Annals of dermatology/Annals of Dermatology”

In this study, simvastatin/ezetimibe treatment led to partial hair regrowth in about 29% of patients with recalcitrant alopecia areata, suggesting it may be a viable alternative therapy for this condition.

research Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies

82 citations , March 2016 in “Autoimmunity reviews”

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism

68 citations , November 2015 in “The Journal of Allergy and Clinical Immunology”

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

176 citations , August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

research Inhibiting Janus Kinases to Treat Alopecia Areata

52 citations , September 2014 in “Nature medicine”

JAK inhibitors might help treat alopecia areata.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

A Randomized, Double-Blind, Placebo- and Active-Controlled, Half-Head Study to Evaluate the Effects of Platelet-Rich Plasma on Alopecia Areata

research A Randomized, Double-Blind, Placebo- and Active-Controlled, Half-Head Study to Evaluate the Effects of Platelet-Rich Plasma on Alopecia Areata

205 citations , April 2013 in “British Journal of Dermatology”

In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.